Introduction {#Sec1}
============

Advances in antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) have meant that patients can achieve a life expectancy near to normal \[[@CR1]\]. However, HIV-infected patients are known to have an increased risk of cardiovascular disease (CVD) compared with the general population, with a significantly elevated mortality rate from cardiovascular (CV) events \[[@CR2]\].

The cause of the increased CVD risk in HIV-infected patients is multifactorial, involving traditional CVD risk factors, HIV infection-associated risk factors, and ART-associated risk factors \[[@CR3]--[@CR6]\]. With improved life expectancy, increased exposure to traditional CVD risk factors, such as tobacco use, dyslipidemia, hypertension, and diabetes, occurs \[[@CR3]\]. HIV infection is associated with increased inflammation, immune dysfunction, and impaired fibrinolysis \[[@CR5]\]. While viral suppression with ART has been associated with an overall reduced risk of CVD events compared to untreated HIV \[[@CR7]\], several studies have suggested that certain antiretrovirals (ARs) are associated with an increased relative risk of CVD \[[@CR3], [@CR8]--[@CR10]\], possibly linked to factors, such as the development of insulin resistance, dyslipidemia, and altered fat distribution \[[@CR6]\]. Abacavir (ABC), didanosine, indinavir, and ritonavir-boosted lopinavir (LPV/r) have been shown to be associated with an increased risk of myocardial infarction (MI) \[[@CR8], [@CR10]\]. Some studies suggest an association between protease inhibitors (PIs) as a drug class and increased CV events among HIV-infected patients, which may be attributable to the proatherogenic effect of these agents on lipids \[[@CR3], [@CR9]\]. Importantly, these early studies did not differentiate between different types of PIs. Other analyses investigating CV risk and PIs have been mixed, with observational trials, but not randomized studies, indicating a relationship between some PIs and increased risk of CVD \[[@CR8]\].

In contrast, the PI atazanavir (ATV) is associated with improved lipid profiles, both in patients with HIV and those with type 1 diabetes without HIV, and improved endothelial function in patients with type 2 diabetes without HIV \[[@CR11]--[@CR13]\]. Ritonavir-boosted ATV (ATV/r) has also been associated with slower progression of carotid intima-media thickness (cIMT)---a surrogate marker for CVD risk---compared with ritonavir-boosted darunavir (DRV/r) and raltegravir (RAL) \[[@CR14]\], potentially due to increased bilirubin caused by ATV. Bilirubin is a known antioxidant that has anti-atherosclerotic properties \[[@CR15]\]. At the same time, ATV-associated hyperbilirubinemia may lead to increased treatment discontinuations, as was shown in AIDS Clinical Trials Group (ACTG) A5257, where ATV/r was equivalent to DRV/r and RAL in risk for virologic failure, but was associated with more discontinuations due to adverse events, leading to the overall inferiority \[[@CR16]\].

To fully elucidate the effect of ATV on CVD risk among HIV-infected patients so as to enable a more complete assessment of its risk/benefit profile, a systematic review of the literature was performed. The aim of this qualitative analysis was to assess CV outcomes among patients with HIV treated with ATV, using both CV event and surrogate marker data, where available. Surrogate markers of atherosclerosis and endothelial dysfunction were included, as both have shown to be independent predictors of CV events \[[@CR17]--[@CR20]\].

Materials and Methods {#Sec2}
=====================

Search Criteria {#Sec3}
---------------

The PubMed and Embase databases were used for the literature search, which was conducted on August 26, 2015. The PubMed search was performed using free text fields and Medical Subject Heading terms to capture studies in patients with HIV infection receiving ART who had experienced adverse CV events (such as coronary artery disease, MI, ischemia, angina, cerebrovascular accident, transient ischemic attack, or peripheral vascular disease). A similar search was conducted using Embase. For detailed terms used, see the Supplementary Material.

For both searches, citations were limited to English-language articles with a publication type of clinical trial, meta-analysis, observational study, cohort study, or case--control study investigating adult humans; no date restriction was placed on the searches. The reference lists of all included papers were hand-searched to identify additional papers. While systematic reviews and meta-analyses were not included in the qualitative analysis, the reference lists of these articles were hand-searched to ensure all eligible studies were identified.

Study Selection {#Sec4}
---------------

Study selection occurred in a two-step process: (1) eligibility was initially assessed using titles and abstracts and (2) those that were not excluded were screened for inclusion/exclusion using the full text. Articles excluded from the analysis were retrospective studies, narrative reviews, editorials, pharmacokinetic studies, pilot studies, animal or in vitro studies, studies in children, and studies in which only the change in lipid profile was reported. Studies of patient subpopulations were excluded unless the population characteristics were generalizable to the adult HIV population. Studies without an ATV arm and those not reporting on outcomes of interest were excluded.

The primary outcome was the incidence of CVD or CV event, defined as coronary heart or artery disease, MI, acute coronary syndrome, thromboembolism, stroke or cerebrovascular events, atherosclerosis, and coronary procedures, such as percutaneous coronary intervention and coronary artery bypass graft. Articles describing surrogate markers of atherosclerosis and endothelial function were also included.

Data Extraction and Assessment of Study Quality {#Sec5}
-----------------------------------------------

Data collected from the articles included study description and trial characteristics, patient characteristics, treatment characteristics, and results/endpoints. Data extraction and validation were performed by MG and LR, respectively. The results of the data extraction were independently reviewed by DC and CS prior to commencing writing of the article. The quality of the included studies was assessed using the methodology checklist of the 2012 National Institute for Health and Care Excellence Guidelines Manual \[[@CR21]\] for the randomized-controlled trials and the 'checklist for measuring study quality' \[[@CR22]\] for the cohort studies.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

A preferred reporting items for systematic reviews and meta-analyses flow diagram showing the screening process and reasons for exclusion is presented in Fig. [1](#Fig1){ref-type="fig"}. A total of 24 studies were identified using PubMed, 77 were identified using Embase, and five were identified from hand searching the reference lists of identified articles. The major reason for excluding articles during the first screening round was that they were not a clinical or cohort study; during the second round of screening, not reporting an outcome of interest was the main reason for article exclusion. In total, ten studies met all criteria and were included in the qualitative analysis (Fig. [1](#Fig1){ref-type="fig"}). Among the included studies, the length of follow-up ranged from 1.5 to 4.8 years, and the studies varied greatly with respect to the ATV-containing and comparator regimens used (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).Fig. 1PRISMA flow diagram of the study selection process Table 1Studies investigating the events of CVD, MI, and strokeStudy and OutcomeStudy design (country; study period; mean follow-up time)Inclusion criteriaExclusion criteriaTreatment (*n*)Number of events (PY)Incidence/1000 PY (95% CI)Effect size^a^ (95% CI)CVD Podzamczer et al. \[[@CR24]\] (ARTEN)RCT in 576 treatment-naïve patients (multicenter; 2006--2011; 4.0 years)HIV-1-infectedNRATV/r + TDF/FTC (193)2^b^NRNRNVP + TDF/FTC (376)2^c^NRNR Sax et al. \[[@CR26]\] (ACTG A5202)RCT in 1060 treatment-naïve patients (USA; 2005--2007; 2.8 years)HIV-infectedChronic hepatitis B infection, pregnant or breastfeeding women, substance abuse, incarceration, or had a serious diseaseABC/3TC + ATV/r (264)15^d^NRNRABC/3TC + EFV (266)14^d^NRNRTDF/FTC + ATV/r (265)15^d^NRNRTDF/FTC + EFV (265)19^d^NRNR Squires et al. \[[@CR25]\] (ARIES)RCT in 515 treatment-naïve patients (USA; 2007--2008; 2.0 years)≥18 years old; HIV-infected; ART-naïve; plasma HIV RNA ≥1000 copies/mLHLA-B\*5701 allele positive; hepatitis B surface antigen positiveABC/3TC + ATV (210)0NRNRABC/3TC + ATV/r (209)2^e^NRNRMI Brouwer et al. \[[@CR28]\]Active-comparator cohort study using North Carolina Medicaid administration data of 3481 treatment-naïve patients (USA; 2002--2008; 1.8 year)≥18 years old; HIV-infected; ≥180 days of Medicaid eligibility prior to study entry; new recipient of cART regimenNew recipients with a regimen dispensed for \<30 days followed by a non-standard cART regimen; patients with any claims for MI, CABG, or PCI in the 180 days prior to cART initiationBoosted/unboosted ATV (543)\<11 (786.5)5.1 (1.9--13.6)1.12 (0.35--3.62)^f^LPV/r (654)\<11 (1325.4)3.8 (1.6--9.1)0.92 (0.26--3.22)^f^NNRTI (1511)13 (2603.9)5.0 (2.9--8.6)1.0ABC (611)15 (1263.8)11.9 (7.2--19.7)2.05 (0.72--5.86)^g^TDF (1605)11 (2433.4)4.5 (2.5--8.2)1.0 Durand et al. \[[@CR29]\]Cohort and nested case--control study using data from the RAMQ and Med-Echo databases of 7494 treatment-experienced patients (Canada; 1985--2007; 4.8 years)Overall cohort: HIV serology positive; receiving ART (excluding lamivudine monotherapy) and matched to HIV-negative patients.\
Nested case--control: HIV-positive patients with acute MI matched to HIV-positive patients without acute MIInadequate coverage with drug insurance (defined as \<6 months of coverage before and 2 months after entry date); age \<20 yearsOverall cohort:All HIV-positive (7053)139 (35,787)3.88 (3.26--4.58)2.11 (1.69--2.63); *p* \< 0.001^h^All HIV-negative (27,681)226 (101,782)2.21 (1.93--2.52)Nested case--control:All cases (125)All matched controls (1084)ATV-exposed cases (7)7NR1.02 (0.42--2.46); NS^i^ATV-unexposed controls (61)0ABC-exposed cases (45)45NR1.79 (1.16--2.76); *p* = 0.008^i^ABC-unexposed controls (251)0EFV-exposed cases (49)49NR1.83 (1.21--2.76); *p* = 0.004^i^EFV-unexposed controls (305)0LPV-exposed cases (41)41NR1.98 (1.24--3.16); *p* = 0.004^i^LPV-unexposed controls (239)0RTV-exposed cases (63)63NR2.29 (1.48--3.54); *p* \< 0.001^i^RTV-unexposed controls (401)0 Monforte et al. \[[@CR30]\] (D:A:D)Cohort study of 79,743 treatment-naïve and -experienced patients (multicenter; 2005--2011) with 37,005 patient--years of ATV expHIV-1 positiveNRNo ATV (NR)740 (264,901)2.79 (2.59--2.99)NRATV 0 to ≤1 year exp41 (13,323)3.08 (2.14--4.02)Relative rate/year of any ATV exp: 0.95 (0.86--1.04)^j^ATV 1 to ≤2 years exp29 (8307)3.49 (2.22--4.76)ATV 2 to ≤3 years exp15 (5974)2.51 (1.41--4.14)ATV \>3 years exp19 (9401)2.02 (1.22--3.16)No ATV/r751 (270,676)2.77 (2.58--2.97)NRATV/r 0 to ≤1 year exp41 (12,039)3.41 (2.36--4.45)Relative rate/year of ATV/r exp: 0.99 (0.90--1.08)^k^ATV/r 1 to ≤2 years exp24 (7110)3.38 (2.03--4.73)ATV/r 2 to ≤3 years exp10 (4863)2.06 (0.99--3.78)ATV/r \>3 years exp18 (7220)2.49 (1.48--3.94)No unboosted ATV821 (292,295)2.81 (2.62--3.00)NRUnboosted ATV 0 to ≤1 year exp15 (4686)3.20 (1.79--5.28)Relative rate/year of unboosted ATV exp: 0.80 (0.61--1.03)^k^Unboosted ATV 1 to ≤2 years exp4 (1967)2.03 (0.55--5.21)Unboosted ATV 2 to ≤3 years exp3 (1227)2.44 (0.50--7.15)Unboosted ATV \>3 years exp1 (1731)0.58 (0.01--3.22)Stroke Monforte et al. \[[@CR30]\] (D:A:D)Cohort study of 79,743 treatment-naïve and -experienced patients (multicenter; 2005--2011) with 37,005 patient--years of ATV expHIV-1 positiveNRNo ATV457 (265,714)1.72 (1.56--1.88)NRATV 0 to ≤1 year exp35 (13,437)2.60 (1.74--3.47)Relative rate/year of any ATV exp: 0.95 (0.87--1.05)^j^ATV 1 to ≤2 years exp14 (7423)1.66 (0.91--2.79)ATV 2 to ≤3 years exp10 (6028)1.66 (0.80--3.05)ATV \>3 years exp16 (9516)1.68 (0.96--2.73)No ATV/r470 (271,560)1.73 (1.57--1.89)NRATV/r 0 to ≤1 year exp27 (12,143)2.22 (1.38--3.06)Relative rate/year of ATV/r exp: 1.02 (0.98--1.06)^k^ATV/r 1 to ≤2 years exp13 (7204)1.80 (0.96--3.09)ATV/r 2 to ≤3 years exp10 (4907)2.04 (0.98--3.75)ATV/r \>3 years exp12 (7304)1.64 (0.85--2.87)No unboosted ATV508 (293,422)1.73 (1.58--1.88)NRUnboosted ATV 0 to ≤1 year exp19 (4696)4.05 (2.44--6.32)Relative rate/year of unboosted ATV exp: 0.80 (0.61--1.03)^k^Unboosted ATV 1 to ≤2 years exp1 (1996)0.50 (0.01--2.79)Unboosted ATV 2 to ≤3 years exp2 (1247)1.60 (0.19--5.78)Unboosted ATV \>3 years exp2 (1756)1.14 (0.14--4.11)*3TC* lamivudine, *ABC* abacavir, *ART* antiretroviral therapy, *ATV* atazanavir, *CABG*, coronary artery bypass graft, *cART* combination antiretroviral therapy, *CI* confidence interval, *CVD* cardiovascular disease, *EFV* efavirenz, *exp* exposure, *FTC* emtricitabine, *HIV* human immunodeficiency virus, *HLA* human leukocyte antigen, *LPV* lopinavir, *MI* myocardial infarction, *NNRTI* non-nucleoside reverse-transcriptase inhibitor, *NR* not reported, *NS* not significant, *NVP* nevirapine, *PCI* percutaneous coronary intervention, *PY* patient-years, *r* ritonavir as pharmacoenhancer, *RAMQ* Régie de l'assurance-maladie du Québec, *RCT* randomized-controlled trial, *RTV* ritonavir (as part of boosted regimen or alone), *TDF* tenofovir disoproxil fumarate^a^Hazard ratio, risk ratio, or odds ratio^b^MI, cardiac failure^c^Angina pectoris, myopericarditis^d^Defined as coronary artery disease, infarct, ischemia, angina, cerebrovascular accident, transient ischemic attack, or peripheral vascular disease^e^Cerebrovascular accident, peripheral vascular disease^f^Propensity score adjusted (inverse probability weighted) hazard ratio versus NNRTI^g^Propensity score adjusted (inverse probability weighted) hazard ratio versus TDF^h^Adjusted odds ratio in HIV-positive patients versus matched HIV-negative patients^i^Adjusted odds ratio of any exposure to the antiretroviral in HIV-positive patients with acute MI (cases) versus no exposure to the antiretroviral in matched HIV-positive patients without acute MI (controls)^j^Adjusted for demographic and clinical confounders, and cumulative/recent exposure to other antiretrovirals^k^Unadjusted Table 2Studies investigating cIMTStudyStudy design (country; study period; mean follow-up time)Inclusion criteriaExclusion criteriaTreatment (*n*)Measure*p* valuede Saint-Martin et al. \[[@CR31]\] (AVATAR)Cohort matched-control study in 132 treatment-experienced patients (France; 2004--2008; 1.5 year)HIV infectionNRMean cIMT, μmATV/r (33)Baseline6336 months64212 months636\<0.05 vs. non-ATV/r18 months611\<0.05 vs. non-ATV/rNon-ATV/r (99)Baseline6666 months66012 months67618 months675Stein et al. \[[@CR14]\] (ACTG A5260 s)RCT in 328 treatment-naïve patients (USA: 2009--2013; 3 years)ART-naïveKnown CVD or diabetesMean (95% CI) cIMT progression, μm/yearATV/r + TDF/FTC (109)8.2 (5.6--10.8)0.013 vs. DRV/r + TDF/FTCDRV/r + TDF/FTC (113)12.9 (10.3--15.5)RAL + TDF/FTC (106)10.7 (9.2--12.2)NS vs. ATV/r or vs. DRV/r*ART* antiretroviral therapy*, ATV* atazanavir, *CI* confidence interval, *cIMT* carotid intima-media thickness, *CVD* cardiovascular disease, *DRV* darunavir, *FTC* emtricitabine, *HIV* human immunodeficiency virus, *NR* not reported, *NS* not significant, *r* ritonavir as pharmacoenhancer, *RAL* raltegravir, *RCT* randomized-controlled trial, *TDF* tenofovir disoproxil fumarate Table 3Studies investigating endothelial functionStudyStudy design (country; study period; mean follow-up time)Inclusion criteriaExclusion criteriaTreatment (*n*)Measure*p* valueFlammer et al. \[[@CR27]\]RCT in 39 treatment-experienced patients (Europe; 2004--2005; 2 years)18--65 years old; HIV-infected; suppressed viral replication with 2 NRTIs and a PIKnown CAD, hypertension, peripheral artery disease, cerebrovascular disease, and diabetesMean (SD) FMD of the brachial arteryUnboosted ATV (20)Baseline4.0% (1.5)24 weeks3.4% (1.7)NS vs. baselineOther PI (19)Baseline3.9% (1.8)24 weeks3.3% (1.4)NS vs. baselineMurphy et al. \[[@CR23]\] (SABAR)RCT in 50 treatment-experienced patients (multicenter; 2005--2007; 2 years)HIV infection; hyperlipidemia;\
stable ARTPrior ATV useMedian (IQR) change in FMD from baseline to 24 weeksATV/r (26)−1.14% (−2.24 to 1.63)NS vs. baselineOther PI (24)+0.25% (−1.58 to 1.84)NS vs. baselineStein et al. \[[@CR14]\] reported that FMD did not change significantly among patients receiving ATV/r, raltegravir, or darunavir/r (*p* \> 0.35)*ART* antiretroviral therapy, *ATV* atazanavir, *CAD* coronary artery disease, *FMD* flow-mediated dilation, *HIV* human immunodeficiency virus, *IQR* interquartile range, *NRTI* nucleoside reverse-transcriptase inhibitor, *NS* not significant, *PI* protease inhibitor, *r* ritonavir, *RCT* randomized-controlled trial, *SD* standard deviation

Quality assessment of the included studies is shown in detail in the Supplementary Material. The included randomized-controlled trials were of moderate quality, mainly because they were either fully open-label studies \[[@CR14], [@CR23]--[@CR25]\] or were only partially blinded to one component of the AR regimen \[[@CR26]\] or to observers \[[@CR27]\]. In addition, one trial showed a significant elevation in triglycerides at baseline in the ATV arm \[[@CR27]\] and two trials showed an imbalance in discontinuation rates between the ATV and comparator arms \[[@CR14], [@CR24]\]. The included cohort studies were of moderate quality, mainly due to the lack of information on patients lost to follow-up, on the representativeness of the study populations and on-treatment compliance.

Of the ten articles included, six reported CVD outcomes \[[@CR24]--[@CR26], [@CR28]--[@CR30]\], two reported data on atherosclerosis as assessed by the surrogate marker cIMT \[[@CR14], [@CR31]\], and two reported outcomes related to endothelial function \[[@CR23], [@CR27]\]. Data were insufficient and outcomes were too varied to conduct a quantitative meta-analysis or to make systematic comparisons between ATV and other ARTs. Therefore, data were compiled qualitatively.

Effect of ATV on CVD Outcomes {#Sec8}
-----------------------------

Of the studies reporting CV outcomes, three were cohort studies and three were randomized-controlled trials (Table [1](#Tab1){ref-type="table"}). Four of the studies included only treatment-naïve patients \[[@CR24]--[@CR26], [@CR28]\], one included both treatment-experienced and -naïve patients \[[@CR30]\], and one included only treatment-experienced patients \[[@CR29]\]. The results of these studies are reported in Table [1](#Tab1){ref-type="table"}.

The studies reporting the incidence of MI in HIV-infected patients showed that ATV was not associated with an increased risk of acute MI. In a cohort of \>16,000 treatment-naïve patients, patients initially treated with both boosted and unboosted ATV (*n* = 543; inverse probability weighted hazard ratio: 1.12; 95% CI 0.35--3.62) or LPV/r (*n* = 654; 0.92; 95% CI 0.26--3.22) did not have an increased rate of MI compared with the initial treatment with a non-nucleoside reverse-transcriptase inhibitor, whereas patients initially treated with ABC (*n* = 611; 2.05; 95% CI 0.72--5.86) trended towards an increased rate of MI compared with tenofovir disoproxil fumarate (TDF) \[[@CR28]\]. Data from the treatment-naïve and -experienced patients included in the D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) study showed no relationship between ATV exposure (37,005 patient years) and an increased MI risk among HIV-infected patients compared with other AR agents, either overall (relative rate/year 0.95; 95% CI 0.86--1.04) or when ATV was given with or without ritonavir (0.99; 95% CI 0.90--1.08 and 0.80; 95% CI 0.61--1.03, respectively) \[[@CR30]\]. In the Durand et al. study, a cohort and nested control analysis of a public health insurance database included 7053 HIV-positive patients, and treatment-experienced patients exposed to ATV with and without ritonavir (number exposed to ATV unknown) did not have an increased risk of MI compared with controls without ATV exposure (*p* = 0.96; Table [1](#Tab1){ref-type="table"}) \[[@CR29]\]. In this analysis, HIV-infected patients exposed to ABC, LPV, or ritonavir had an increased risk of acute MI (odds ratios 1.79, 1.98, and 2.29, respectively; *p* \< 0.01 vs. matched controls) \[[@CR29]\].

Other CV endpoints were similarly unaffected by treatment with ATV. The D:A:D study examined the risk of stroke among HIV-infected patients exposed to ATV and found no association between ATV and an increased stroke risk (overall 0.95; 95% CI 0.87--1.05; boosted 1.02; 95% CI 0.98--1.06; unboosted 0.80; 95% CI 0.61--1.03) \[[@CR30]\] (Table [1](#Tab1){ref-type="table"}).

Of the three randomized-controlled trials reporting a variety of CV endpoints (a composite of coronary artery disease, infarct, ischemia, angina, transient ischemic attack, cerebrovascular accident, or peripheral vascular disease \[[@CR26]\] or unspecified CV adverse events \[[@CR24], [@CR25]\]), there was no increase in CV events among HIV-infected patients receiving ATV (*n* = 1141). In the ACTG study A5202, there was a low incidence of CV events overall in patients receiving ABC/lamivudine or TDF/emtricitabine (FTC) plus ATV/r or efavirenz, with no difference between treatment groups \[[@CR26]\]. In the studies reporting unspecified CV adverse events, there was one occurrence each of MI and cardiac failure among patients receiving ATV/r and one occurrence each of angina pectoris and myopericarditis among patients receiving nevirapine through 4 years of follow-up (Table [1](#Tab1){ref-type="table"}) \[[@CR24]\], and in the randomized open-label ARIES study (ClinicalTrials.gov identifier: NCT00440947), one occurrence of cerebrovascular accident and one of peripheral vascular disease in treatment-naïve patients treated with ATV with or without ritonavir in combination with ABC/lamivudine \[[@CR25]\].

Effect of ATV on Markers of Atherosclerosis {#Sec9}
-------------------------------------------

Two studies investigated the effect of ATV on atherosclerosis using changes in cIMT. One was a prospective, randomized-controlled ACTG substudy (A5260 s) in treatment-naïve patients, while the other was a single-center, prospective matched-control cohort study in treatment-experienced patients (Table [2](#Tab2){ref-type="table"}) \[[@CR14], [@CR31]\].

Overall, the results of the cIMT measurements showed that treatment with ATV was associated with beneficial effects on cIMT progression compared with non-ATV-based regimens (Table [2](#Tab2){ref-type="table"}). In the ACTG 5260 s study, patients received either TDF/FTC plus either ATV/r (*n* = 109), DRV/r (*n* = 113), or RAL (*n* = 106) for 144 weeks. At study end, increases in cIMT at the common carotid artery (primary intent-to-treat analysis) had progressed more slowly in patients receiving ATV/r than in those receiving DRV/r or RAL; however, differences reached statistical significance in the comparison with DRV/r (*p* = 0.013) but not with RAL (*p* = 0.15) \[[@CR14]\]. In the on-treatment analysis and at the carotid bifurcation, ATV/r was associated with significantly slower cIMT progression compared with both DRV and RAL \[[@CR14]\]. In the cohort study, patients receiving regimens, including ATV/r (*n* = 33), had significantly decreased cIMT compared with matched controls not receiving ATV/r (*n* = 99) after 12 and 18 months of therapy (*p* ≤ 0.05 for both) \[[@CR31]\]. The differences in cIMT progression remained significant after adjustment for differences in baseline demographics.

Effect of ATV on Endothelial Function {#Sec10}
-------------------------------------

Two randomized-controlled trials in treatment-experienced patients with HIV assessed endothelial function via flow-mediated dilation (FMD) of the brachial artery \[[@CR23], [@CR27]\] (Table [3](#Tab3){ref-type="table"}). There was no impact of ATV therapy on endothelial function in these studies (Table [3](#Tab3){ref-type="table"}). Both the randomized-controlled trials investigated switching from another PI to ATV (with or without ritonavir) with a trial duration of 24 weeks. In patients receiving unboosted ATV (*n* = 20), there was no change in FMD compared with the previous PI therapy (*p* = 0.40) \[[@CR27]\], and patients receiving ATV/r (*n* = 26) did not demonstrate any significant change in FMD both from baseline and versus patients continuing on the previous PI/r therapy (*p* = 0.64 after adjustment for brachial artery diameter changes) \[[@CR23]\]. Endothelial function was also measured in the ACTG A5260 s study. FMD did not change significantly among patients treated with ATV/r, RAL, or DRV/r. In addition, despite the differences seen in cIMT progression, there were no differences in FMD change between treatment arms \[[@CR14]\].

Discussion {#Sec11}
==========

This systematic literature review concerning ATV and CVD risk among patients with HIV showed no relationship between boosted and unboosted ATV and an increased risk for CV clinical outcome events, including MI and stroke. The use of ATV was associated with improvements in surrogate markers of atherosclerosis compared with non-ATV-based regimens, and the studies analyzed showed no impact of ATV on endothelial function.

This study did not investigate the impact of ATV on lipid levels in HIV-infected patients, as previous studies have explored this \[[@CR11], [@CR32]\]. In one systematic study, ATV was associated with lower lipid levels compared with a pooled cohort of other ritonavir-boosted PI regimens \[[@CR11]\]. A second study of ritonavir-boosted PIs found that patients treated with ATV had cholesterol and triglyceride elevations that were lower than LPV or fosamprenavir but similar to saquinavir or DRV \[[@CR32]\]. It is not entirely clear what contributions lipid elevations make to the overall CV risk. In the ACTG A5260 s study, ATV/r was associated with slower atherosclerosis progression compared to DRV/r and RAL, despite RAL having smaller increases in lipid parameters than the boosted PI arms \[[@CR14]\].

One potential explanation for this apparent discrepancy is ATV-induced hyperbilirubinemia, which is a common laboratory abnormality associated with ATV treatment. Bilirubin has been shown to have antioxidant, anti-inflammatory, and antiatherogenic properties and is thought to result in protection from CVD \[[@CR33], [@CR34]\]. Multiple studies have shown that individuals with Gilbert syndrome, a genetic deficiency in UGT1A1 resulting in chronic low level hyperbilirubinemia, have a reduced risk for CV events compared with the general population \[[@CR35]--[@CR38]\]. ATV has been shown to increase bilirubin levels and reduce levels of oxidative stress in HIV-infected patients compared with non-ATV-based treatment \[[@CR23], [@CR39]\]. Additional studies have also linked increasing bilirubin levels with slower atherosclerosis progression (as measured by cIMT) \[[@CR14], [@CR40]\], which suggests that there may be a relationship between ATV therapy, bilirubin levels and improvements in oxidative stress, atherosclerosis, and CV risk.

Due to its impact on bilirubin and the anti-atherosclerotic properties of bilirubin, ATV has been studied in non-HIV-infected patients with type 1 and 2 diabetes. In patients with type 1 diabetes, the initiation of ATV decreased lipid parameters and increased total plasma antioxidant capacity from baseline; however, similar to the studies of HIV-infected patients analyzed in this review, it did not result in an improvement in endothelial function \[[@CR12]\]. In an experimental double-blind, placebo-controlled crossover study of HIV-negative patients with type 2 diabetes, ATV was associated with a significant improvement in both plasma antioxidant capacity and endothelial function \[[@CR13]\].

Recent studies published after the search for this analysis was initiated are consistent with the results described here. In an analysis of data from HIV-infected patients in the Veterans Health Administration Clinical Case Registry, exposure to ATV was not associated with an increased risk of CV events \[[@CR41]\]. Moreover, in a retrospective, longitudinal study of patients with HIV in Brazil, the recent boosted ATV exposure was associated with a decreased risk of CV outcome events \[[@CR42]\]. Finally, in a retrospective analysis of the Hawaii Aging with HIV CV Study, patients receiving ATV/r had a slower progression of cIMT over 2 years compared with those not receiving ATV/r (9 µm vs. 22 µm; *p* \< 0.001). These differences remained significant after adjusting for age, sex, and other CVD-related comorbidities (*p* = 0.012). Similar to the ACTG A5260 s study, there was a significant inverse correlation between increasing baseline total serum bilirubin and reduced cIMT progression \[[@CR40]\].

This analysis has limitations. First, a small number of studies were identified with relatively few ATV patients. This combined with the variable forms of data presentation and outcomes prevented a meta-analysis from being performed. Second, data were insufficient to make any assessment of differences in CV outcomes with unboosted ATV versus ritonavir-boosted ATV. Third, studies solely investigating lipid levels were not included, and no attempt was made to account for concomitant medications, such as statins, or baseline comorbidities, or to weight evidence according to its source, i.e., from randomized-controlled studies or from studies performed under real-world conditions. Fourth, patients included in these analyses had variable durations of HIV infection, AR experience, and were exposed to a wide variety of ART regimens. Given the relatively limited information identified in this review, larger cohort studies are needed to better evaluate the relative risk of CVD with ATV versus other contemporary ARs in patients with HIV infection.

Conclusions {#Sec12}
===========

In this systematic review of CVD in HIV-infected patients receiving ATV, a limited number of studies were identified. In the identified studies, there was no increase in the risk or occurrence of adverse CV clinical outcome events with boosted and unboosted ATV compared to other AR agents. Endothelial function was not affected by ATV, while ATV use was associated with improvements in markers of atherosclerosis. These findings should be taken into consideration when selecting HIV treatment for individuals at increased risk of CVD.
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